

# Michael L Friedlander

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5500656/publications.pdf>

Version: 2024-02-01

320  
papers

33,594  
citations

9775

73  
h-index

4112

175  
g-index

329  
all docs

329  
docs citations

329  
times ranked

27901  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. <i>Journal of Cancer Survivorship</i> , 2022, 16, 223-232.	1.5	16
2	The validity of progression-free survival 2 as a surrogate trial end point for overall survival. <i>Cancer</i> , 2022, 128, 1449-1457.	2.0	15
3	Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. <i>Gynecologic Oncology</i> , 2022, 165, 40-48.	0.6	10
4	Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100504.	0.7	1
5	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial. <i>Gynecologic Oncology</i> , 2022, 164, 278-287.	0.6	6
6	Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment) Tj ETQq0 0 0 rgBT/Overlook 10 Tf 50	0.6	10
7	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. <i>Gynecologic Oncology</i> , 2022, 164, 245-253.	0.6	15
8	Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline <i>BRCA</i> Pathogenic Variants: A Cause for Concern or Potentially Avoidable?. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200325.	0.8	0
9	TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102108.	0.8	3
10	Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003009.	1.2	0
11	Germline BRCA variants, lifestyle and ovarian cancer survival. <i>Gynecologic Oncology</i> , 2022, , .	0.6	2
12	Interobserver and intraobserver variability of RECIST assessment in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 656-661.	1.2	2
13	Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 170, 169-178.	1.3	2
14	A multicenter phase II randomized trial of durvalumab (D) versus physician's choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5565-5565.	0.8	7
15	Abstract LB511: The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab. <i>Cancer Research</i> , 2022, 82, LB511-LB511.	0.4	0
16	Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 166, 254-262.	0.6	5
17	Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6518-6518.	0.8	1
18	Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial. <i>Supportive Care in Cancer</i> , 2021, 29, 1103-1110.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Pre- and Post-Diagnosis Diet Quality and Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 229-232.	1.1	14
20	Abstract PS11-03: Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germline BRCA1 or BRCA2 mutations from the phase 3 BROCADE3 trial. , 2021, , .		0
21	Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. <i>Oncologist</i> , 2021, 26, 366-374.	1.9	12
22	Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. <i>Cancer</i> , 2021, 127, 2432-2441.	2.0	14
23	Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting. <i>European Journal of Cancer</i> , 2021, 148, 251-259.	1.3	2
24	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. <i>British Journal of Cancer</i> , 2021, 125, 265-276.	2.9	7
25	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 632-642.	5.1	40
26	REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 374-381.	0.6	17
27	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 620-631.	5.1	215
28	Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIg symptom benefit committee. <i>Gynecologic Oncology</i> , 2021, 161, 502-507.	0.6	3
29	Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5584-5584.	0.8	1
30	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1669-1680.	1.1	5
31	Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. , 2021, 9, e002255.		61
32	Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover). <i>Clinical Cancer Research</i> , 2021, 27, 4983-4993.	3.2	9
33	Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , 2021, 5, 1151-1159.	1.5	16
34	Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. <i>Gynecologic Oncology</i> , 2021, 163, 41-49.	0.6	17
35	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. <i>Gynecologic Oncology</i> , 2021, 162, 375-381.	0.6	7
36	Bilateral Salpingo-oophorectomy and Breast Cancer Risk for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Assessing the Evidence. <i>Cancer Prevention Research</i> , 2021, 14, 983-994.	0.7	8

#	ARTICLE	IF	CITATIONS
37	A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. <i>Gynecologic Oncology</i> , 2021, 163, 72-78.	0.6	17
38	Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment. <i>Gynecologic Oncology</i> , 2021, 163, 398-407.	0.6	5
39	1429Impact of BRCA mutation status and lifestyle factors on survival among women with ovarian cancer. <i>International Journal of Epidemiology</i> , 2021, 50, .	0.9	0
40	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021, 154, 190-200.	1.3	9
41	Efficacy and safety of first-line veliparib and carboplatin+paclitaxel in patients with HER2+ advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 154, 35-45.	1.3	10
42	The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer. , 2021, , 43-53.		0
43	Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians. <i>Cancer Prevention Research</i> , 2021, 14, 131-144.	0.7	6
44	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 61-85.	1.0	145
45	Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1721-1731.	5.1	172
46	Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa110.	1.4	4
47	Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. <i>Scientific Reports</i> , 2021, 11, 22884.	1.6	11
48	The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?. <i>Cancer Management and Research</i> , 2021, Volume 13, 8457-8471.	0.9	10
49	Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110596.	1.4	9
50	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab090.	1.4	1
51	Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis. <i>Journal of Geriatric Oncology</i> , 2020, 11, 508-514.	0.5	23
52	Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results. <i>Journal of the National Cancer Institute</i> , 2020, 112, 418-422.	3.0	1
53	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. <i>Cancer Research</i> , 2020, 80, 116-125.	0.4	37
54	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. <i>European Journal of Cancer</i> , 2020, 139, 59-67.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
56	Insomnia and its association with quality of life in women with ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 760-768.	0.6	17
57	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3528-3537.	0.8	64
58	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1269-1282.	5.1	207
59	Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials. <i>JAMA Network Open</i> , 2020, 3, e2011809.	2.8	33
60	When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 179-186.	0.6	20
61	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
62	A healthy lifestyle and survival among women with ovarian cancer. <i>International Journal of Cancer</i> , 2020, 147, 3361-3369.	2.3	16
63	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 2140-2150.	0.8	68
64	A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1239-1242.	1.2	14
65	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 368-378.	1.1	24
66	Should MMT still be treated with adjuvant taxane-based combination chemotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 695-704.	1.2	5
67	392...Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study. , 2020, , .		2
68	Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1091-1091.	0.8	1
69	Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1097-1097.	0.8	2
70	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6002-6002.	0.8	75
71	Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6068-6068.	0.8	6
72	PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6077-6077.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6014-6014.	0.8	2
74	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1306-1315.	5.1	87
75	Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 1023-1032.	0.6	21
76	Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. <i>European Journal of Cancer</i> , 2019, 117, 99-106.	1.3	17
77	OVQUEST â€“ Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. <i>Gynecologic Oncology</i> , 2019, 155, 126-134.	0.6	26
78	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2403-2415.	13.9	627
79	Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , 2019, 133, 245-254.	1.2	38
80	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2019, 154, 531-538.	0.6	49
81	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial â€“ ANZGOG 0903. <i>Gynecologic Oncology</i> , 2019, 154, 29-37.	0.6	35
82	Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. <i>Clinical Cancer Research</i> , 2019, 25, 3962-3973.	3.2	36
83	Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. <i>International Journal of Cancer</i> , 2019, 145, 370-379.	2.3	9
84	10-year performance of four models of breast cancer risk: a validation study. <i>Lancet Oncology</i> , The, 2019, 20, 504-517.	5.1	116
85	Do all patients with recurrent ovarian cancer need systemic therapy?. <i>Cancer</i> , 2019, 125, 4602-4608.	2.0	4
86	Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). <i>Breast Cancer Research</i> , 2019, 21, 128.	2.2	27
87	The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 271-278.	1.1	31
88	Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. <i>British Journal of Cancer</i> , 2019, 120, 279-285.	2.9	17
89	Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5501-5501.	0.8	46
90	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e86.	1.0	18



#	ARTICLE	IF	CITATIONS
91	How long have we got? The accuracy of physicians'™ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).. Journal of Clinical Oncology, 2019, 37, 5549-5549.	0.8	0
92	Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.. Journal of Clinical Oncology, 2019, 37, 5539-5539.	0.8	4
93	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers. JAMA Oncology, 2018, 4, 522.	3.4	92
94	Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Quality of Life Research, 2018, 27, 59-74.	1.5	40
95	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2018, 24, 569-580.	3.2	79
96	Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIg Symptom Benefit Study (SBS). Gynecologic Oncology, 2018, 148, 36-41.	0.6	26
97	A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve. Oncologist, 2018, 23, 203-213.	1.9	28
98	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	1.4	21
99	Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 459-464.	0.7	4
100	The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Related Outcome Measures, 2018, Volume 9, 353-367.	0.7	295
101	Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). Breast Cancer Research, 2018, 20, 132.	2.2	51
102	The value of participating in clinical trials: the whole is greater than the sum of its parts. Medical Journal of Australia, 2018, 209, 424.	0.8	2
103	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	1.4	33
104	Medicare-funded cancer genetic tests: a note of caution. Medical Journal of Australia, 2018, 209, 193-196.	0.8	10
105	Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology and Obstetrics, 2018, 143, 59-78.	1.0	205
106	Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer, 2018, 119, 1075-1085.	2.9	133
107	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 2018, 379, 2495-2505.	13.9	1,854
108	Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. Gynecologic Oncology, 2018, 150, 527-533.	0.6	14

#	ARTICLE	IF	CITATIONS
109	A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e81.	1.0	7
110	Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2018, 19, 1126-1134.	5.1	113
111	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 151, 18-23.	0.6	18
112	Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878850.	1.4	4
113	Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. <i>Supportive Care in Cancer</i> , 2018, 26, 4133-4142.	1.0	29
114	Tumour profiling for treatment of patients with ovarian cancers. <i>Pathology</i> , 2018, 50, S77.	0.3	0
115	Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10062-10062.	0.8	2
116	The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10081-10081.	0.8	4
117	AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancerâ€”Overall survival (OS) results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5518-5518.	0.8	7
118	PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5524-5524.	0.8	8
119	Inter and intra-observer variability with the assessment of RECIST in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5555-5555.	0.8	1
120	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 48-48.	0.8	12
121	Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.. <i>Journal of Clinical Oncology</i> , 2018, 36, 445-445.	0.8	1
122	P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS574-TPS574.	0.8	0
123	The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 155-155.	0.8	0
124	The Ovarian cancer Prognosis And Lifestyle (OPAL) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 88-88.	0.8	2
125	When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 172-172.	0.8	0
126	P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4596-TPS4596.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.. Journal of Clinical Oncology, 2018, 36, 5556-5556.	0.8	1
128	Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.. Journal of Clinical Oncology, 2018, 36, 5568-5568.	0.8	0
129	REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC).. Journal of Clinical Oncology, 2018, 36, 10097-10097.	0.8	1
130	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 145, 122-129.	0.6	21
131	A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 269-285.	1.4	44
132	Paragon (ANZGOG-0903). International Journal of Gynecological Cancer, 2017, 27, 900-906.	1.2	17
133	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. Journal of Pain and Symptom Management, 2017, 54, 74-84.	0.6	45
134	The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Human Reproduction, 2017, 32, 1033-1045.	0.4	110
135	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer. European Journal of Cancer, 2017, 78, 133-138.	1.3	31
136	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	3.8	1,898
137	Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2017, 7, 984-998.	7.7	310
138	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1274-1284.	5.1	1,376
139	Resisting RECIST Uniformity Versus Clinical Validity. International Journal of Gynecological Cancer, 2017, 27, 1619-1627.	1.2	1
140	What is the role of retroperitoneal exploration in optimally debulked stage IIIc epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer, 2017, 123, 985-993.	2.0	13
141	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology, 2017, 13, 307-320.	1.1	41
142	Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 126-138.	1.4	32
143	A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. Journal of Patient-Reported Outcomes, 2017, 1, 5.	0.9	23
144	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 3013-3013.	0.8	20

#	ARTICLE	IF	CITATIONS
145	Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.. Journal of Clinical Oncology, 2017, 35, 5506-5506.	0.8	13
146	Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.. Journal of Clinical Oncology, 2017, 35, 5507-5507.	0.8	14
147	Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. Journal of Clinical Oncology, 2017, 35, 5533-5533.	0.8	20
148	Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget, 2017, 8, 47154-47160.	0.8	23
149	P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).. Journal of Clinical Oncology, 2017, 35, TPS4592-TPS4592.	0.8	0
150	Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).. Journal of Clinical Oncology, 2017, 35, 5575-5575.	0.8	1
151	Should MMT of the endometrium/ovary be treated with anthracycline instead of taxane based chemotherapy?. Journal of Clinical Oncology, 2017, 35, 5563-5563.	0.8	0
152	Phase I study of olaparib (O), in combination with oral cyclophosphamide (C), in patients (pts) with metastatic triple negative breast cancer (TNBC) and recurrent high grade serous ovarian cancer (OVCA).. Journal of Clinical Oncology, 2017, 35, 1104-1104.	0.8	0
153	Neoadjuvant chemoradiation (modified Eilber protocol) versus adjuvant radiotherapy in the treatment of extremity soft tissue sarcoma. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 539-544.	0.9	8
154	Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 323-331.	0.7	32
155	Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. BMC Medical Ethics, 2016, 17, 63.	1.0	1
156	Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?. Supportive Care in Cancer, 2016, 24, 2627-2634.	1.0	15
157	Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Human Reproduction, 2016, 31, 1126-1132.	0.4	84
158	Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncology, The, 2016, 17, 1579-1589.	5.1	380
159	Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer, 2016, 115, 1313-1320.	2.9	52
160	The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. Quality of Life Research, 2016, 25, 2457-2465.	1.5	37
161	Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine) Tj ETQq1 1 0.784314 rgBT/Ov	4.1	14
162	Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecologic Oncology, 2016, 140, 199-203.	0.6	252

#	ARTICLE	IF	CITATIONS
163	BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. <i>Gynecologic Oncology</i> , 2016, 140, 443-449.	0.6	47
164	Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 648-654.	1.2	69
165	Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer – a population-based study. <i>Acta Oncologica</i> , 2016, 55, 226-233.	0.8	15
166	Risk of uterine cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1529-1529.	0.8	1
167	A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3066-3066.	0.8	3
168	Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2016, 34, 5501-5501.	0.8	9
169	Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5520-5520.	0.8	5
170	Where have we gone wrong? Phase II trials (Ph2t) do not inform the results of phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5559-5559.	0.8	4
171	Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5575-5575.	0.8	2
172	Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. <i>Oncotarget</i> , 2016, 7, 19840-19849.	0.8	23
173	Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16056-e16056.	0.8	0
174	Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5508-5508.	0.8	1
175	Whole – genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015, 521, 489-494.	13.7	1,206
176	Reply to M.G. McNamara et al and M.S. Copur et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 2583-2584.	0.8	0
177	Outcomes and endpoints in cancer trials: bridging the divide. <i>Lancet Oncology</i> , The, 2015, 16, e43-e52.	5.1	72
178	Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial. <i>Gynecologic Oncology</i> , 2015, 136, 37-42.	0.6	29
179	Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. <i>Gynecologic Oncology</i> , 2015, 136, 18-24.	0.6	39
180	Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation. <i>Journal of Clinical Oncology</i> , 2015, 33, 244-250.	0.8	1,473

#	ARTICLE	IF	CITATIONS
181	Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology and Obstetrics, 2015, 131, S111-22.	1.0	70
182	Dry eyes and AIs: If you don't ask you won't find out. Breast, 2015, 24, 694-698.	0.9	21
183	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncology, The, 2015, 16, 87-97.	5.1	491
184	Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy.. Journal of Clinical Oncology, 2015, 33, 5547-5547.	0.8	2
185	TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.. Journal of Clinical Oncology, 2015, 33, 9571-9571.	0.8	4
186	Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).. Journal of Clinical Oncology, 2015, 33, TPS1102-TPS1102.	0.8	3
187	Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. Medical Journal of Australia, 2014, 201, 283-288.	0.8	56
188	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer, 2014, 14, 993.	1.1	23
189	Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer. International Journal of Gynecological Cancer, 2014, 24, 865-873.	1.2	30
190	“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?. Gynecologic Oncology, 2014, 133, 624-631.	0.6	305
191	Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. Journal of Clinical Oncology, 2014, 32, 3374-3382.	0.8	302
192	Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs. Gynecologic Oncology, 2014, 132, 690-697.	0.6	92
193	Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 2014, 32, 1309-1316.	0.8	154
194	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 852-861.	5.1	1,237
195	Molecular profiling of clear cell ovarian carcinoma.. Journal of Clinical Oncology, 2014, 32, 5516-5516.	0.8	1
196	Characterization of ovarian cancer long-term responders on olaparib.. Journal of Clinical Oncology, 2014, 32, 5534-5534.	0.8	1
197	A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).. Journal of Clinical Oncology, 2014, 32, TPS5632-TPS5632.	0.8	10
198	Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned?., 2014, , 91-100.		0

#	ARTICLE	IF	CITATIONS
199	The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5627-TPS5627.	0.8	1
200	Measuring subjective improvement of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/ GCIG/PoCoG).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5615-TPS5615.	0.8	1
201	The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5621-TPS5621.	0.8	0
202	Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. <i>J Clin Oncol</i> 2013;(suppl; abstr 3). <i>Chinese Clinical Oncology</i> , 2014, 3, 6.	0.4	20
203	Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. <i>Clinical Cancer Research</i> , 2013, 19, 5485-5493.	3.2	126
204	Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2013, 31, 3091-3099.	0.8	148
205	Primary Surgical Management With Tailored Adjuvant Radiation for Stage IB2 Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2013, 121, 765-772.	1.2	10
206	Genome-Wide Association Study in <i>BRCA1</i> Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
207	A Fibroid or Cancer? A Rare Case of Mixed Choriocarcinoma and Epithelioid Trophoblastic Tumour. <i>Case Reports in Obstetrics and Gynecology</i> , 2013, 2013, 1-2.	0.2	9
208	Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently?. <i>Journal of Clinical Oncology</i> , 2013, 31, 2362-2362.	0.8	27
209	Communication and Information Needs of Women Diagnosed With Ovarian Cancer Regarding Treatment-Focused Genetic Testing. <i>Oncology Nursing Forum</i> , 2013, 40, 275-283.	0.5	39
210	Do <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuninghame Foundation Consortium for Research Into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3920-3925.	0.8	42
211	Chemotherapy-induced peripheral neurotoxicity: A critical analysis. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 419-437.	157.7	547
212	Preventing breast and ovarian cancers in high-risk <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Medical Journal of Australia</i> , 2013, 199, 680-683.	0.8	39
213	Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 359.	1.0	16
214	Olaparib monotherapy in patients with advanced cancer and a germ-line <i>BRCA1/2</i> mutation: An open-label phase II study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11024-11024.	0.8	17
215	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a <i>BRCA</i> mutation ( <i>BRCAM</i> ).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5505-5505.	0.8	27
216	Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5542-5542.	0.8	9



#	ARTICLE	IF	CITATIONS
217	The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).. Journal of Clinical Oncology, 2013, 31, 9602-9602.	0.8	1
218	PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.. Journal of Clinical Oncology, 2013, 31, TPS5614-TPS5614.	0.8	3
219	Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).. Journal of Clinical Oncology, 2013, 31, LBA5503-LBA5503.	0.8	35
220	Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).. Journal of Clinical Oncology, 2013, 31, LBA5503-LBA5503.	0.8	11
221	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 2012, 72, 4060-4073.	0.4	100
222	Breast Cancer Prognosis in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study. Journal of Clinical Oncology, 2012, 30, 19-26.	0.8	134
223	Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study. Journal of Clinical Oncology, 2012, 30, 1805-1812.	0.8	114
224	Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology and Obstetrics, 2012, 119, S118-29.	1.0	194
225	Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer, 2012, 20, 2959-2967.	1.0	93
226	How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. BMC Cancer, 2012, 12, 320.	1.1	23
227	Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. New England Journal of Medicine, 2012, 366, 1382-1392.	13.9	1,595
228	<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 2012, 30, 2654-2663.	0.8	1,018
229	Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With <i>BRCA1</i> or <i>BRCA2</i> Mutations and Recurrent Ovarian Cancer. Journal of Clinical Oncology, 2012, 30, 372-379.	0.8	445
230	Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with <i>BRCA1/2</i> mutations.. Journal of Clinical Oncology, 2012, 30, 3048-3048.	0.8	12
231	Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials.. Journal of Clinical Oncology, 2012, 30, 4531-4531.	0.8	1
232	Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.. Journal of Clinical Oncology, 2012, 30, 5001-5001.	0.8	50
233	Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).. Journal of Clinical Oncology, 2012, 30, 5081-5081.	0.8	3
234	Predictors of resilience in women treated for breast cancer: A prospective study.. Journal of Clinical Oncology, 2012, 30, 9044-9044.	0.8	3



#	ARTICLE	IF	CITATIONS
235	A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS5116-TPS5116.	0.8	4
236	Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. <i>Experimental Neurology</i> , 2011, 227, 120-127.	2.0	18
237	The Role of Hormonal Therapy in Gynecological Cancers-Current Status and Future Directions. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1.	1.2	26
238	A Specialist Breast Care Nurse Role for Women With Metastatic Breast Cancer: Enhancing Supportive Care. <i>Oncology Nursing Forum</i> , 2011, 38, 627-631.	0.5	13
239	Carboplatin Dosing in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1.	1.2	14
240	Development and Pilot Testing of a Fertility Decision Aid for Young Women Diagnosed with Early Breast Cancer. <i>Breast Journal</i> , 2011, 17, 112-114.	0.4	42
241	The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 197-211.	0.7	13
242	A response to the forgotten fallopian tube. <i>Nature Reviews Cancer</i> , 2011, 11, 227-227.	12.8	0
243	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	12.8	1,084
244	Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. <i>Muscle and Nerve</i> , 2011, 43, 367-374.	1.0	69
245	Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From <i>BRCA1/2</i> -Associated Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4224-4226.	0.8	23
246	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2538-2548.	3.2	217
247	Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1338-1342.	3.0	33
248	Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. <i>Oncologist</i> , 2011, 16, 708-716.	1.9	171
249	It's Now or Never: Fertility-Related Knowledge, Decision-Making Preferences, and Treatment Intentions in Young Women With Breast Cancer—An Australian Fertility Decision Aid Collaborative Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1670-1677.	0.8	171
250	Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment?. <i>Journal of Clinical Oncology</i> , 2011, 29, e553-e554.	0.8	8
251	If I Am in the Mood, I Enjoy It: An Exploration of Cancer-Related Fatigue and Sexual Functioning in Women with Breast Cancer. <i>Oncologist</i> , 2011, 16, 1333-1344.	1.9	84
252	Clinical Trials in Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 771-775.	1.2	186

#	ARTICLE	IF	CITATIONS
253	Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIg). International Journal of Gynecological Cancer, 2011, 21, 419-423.	1.2	500
254	2010 Gynecologic Cancer InterGroup (GCIg) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference. International Journal of Gynecological Cancer, 2011, 21, 750-755.	1.2	361
255	Dose Effects of Oxaliplatin on Persistent and Transient Na <sup>+</sup> Conductances and the Development of Neurotoxicity. PLoS ONE, 2011, 6, e18469.	1.1	61
256	Squamous Cell Carcinomas Arising From Dermoids. , 2011, , 131-133.		0
257	Moving Toward Personalized Medicine: Treatment-Focused Genetic Testing of Women Newly Diagnosed With Ovarian Cancer. International Journal of Gynecological Cancer, 2010, 20, 704-716.	1.2	27
258	Malignant Transformation Within Ovarian Dermoid Cysts. International Journal of Gynecological Cancer, 2010, 20, 75-81.	1.2	15
259	Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Research and Treatment, 2010, 120, 715-723.	1.1	29
260	A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecologic Oncology, 2010, 119, 32-37.	0.6	228
261	Current Academic Clinical Trials in Ovarian Cancer. International Journal of Gynecological Cancer, 2010, 20, 1290-1298.	1.2	7
262	Assessing Health-Related Quality of Life in Gynecologic Oncology. International Journal of Gynecological Cancer, 2010, 20, 664-684.	1.2	53
263	The role of BRCA mutation testing in determining breast cancer therapy. Nature Reviews Clinical Oncology, 2010, 7, 708-717.	12.5	85
264	The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 492-499.	0.8	42
265	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, The, 2010, 376, 235-244.	6.3	1,584
266	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, The, 2010, 376, 245-251.	6.3	1,596
267	Optimally Debulked Stage III Ovarian Cancer: Intraperitoneal or Intravenous Chemotherapy?. International Journal of Gynecological Cancer, 2010, 20, S20-S23.	1.2	4
268	Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. Journal of Clinical Oncology, 2009, 27, 1419-1425.	0.8	645
269	Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials. Journal of Clinical Oncology, 2009, 27, 5109-5114.	0.8	50
270	Oxaliplatin-Induced Lhermitte's Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. Oncology, 2009, 77, 342-348.	0.9	21

#	ARTICLE	IF	CITATIONS
271	Prediagnosis Reproductive Factors and All-Cause Mortality for Women with Breast Cancer in the Breast Cancer Family Registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1792-1797.	1.1	32
272	Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity. <i>Journal of Clinical Oncology</i> , 2009, 27, 1243-1249.	0.8	153
273	Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 167-176.	1.1	20
274	The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 215-223.	1.1	188
275	Younger age-at-diagnosis for familial malignant testicular germ cell tumor. <i>Familial Cancer</i> , 2009, 8, 451-456.	0.9	21
276	Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor. <i>European Journal of Cancer</i> , 2009, 45, 3262-3270.	1.3	48
277	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. <i>Brain</i> , 2009, 132, 2712-2723.	3.7	198
278	Symptom Control in Patients With Recurrent Ovarian Cancer: Measuring the Benefit of Palliative Chemotherapy in Women With Platinum Refractory/Resistant Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, S44-S48.	1.2	29
279	Selective sensitivity to carboxamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. <i>International Journal of Cancer</i> , 2008, 123, 258-263.	2.3	10
280	Analysis of the <i>DND1</i> gene in men with sporadic and familial testicular germ cell tumors. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 247-252.	1.5	37
281	The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions. <i>Breast</i> , 2008, 17, 436-440.	0.9	44
282	Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. <i>Breast Cancer Research</i> , 2008, 10, 216.	2.2	42
283	Cancer Risk Management Practices of Noncarriers Within <i>BRCA1/2</i> Mutation-Positive Families in the Kathleen Cuninghame Foundation Consortium for Research Into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 225-232.	0.8	19
284	Prostate screening uptake in Australian <i>BRCA1</i> and <i>BRCA2</i> carriers. <i>Hereditary Cancer in Clinical Practice</i> , 2007, 5, 161.	0.6	3
285	Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. <i>Clinical Colorectal Cancer</i> , 2007, 6, 578-582.	1.0	3
286	Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. <i>Gynecologic Oncology</i> , 2007, 106, 44-51.	0.6	33
287	The Experience of Cancer-Related Fatigue and Chronic Fatigue Syndrome: A Qualitative and Comparative Study. <i>Journal of Pain and Symptom Management</i> , 2007, 34, 126-135.	0.6	59
288	Addition of Gabapentin to a Modified FOLFOX Regimen Does Not Reduce Oxaliplatin-Induced Neurotoxicity. <i>Clinical Colorectal Cancer</i> , 2006, 6, 146-151.	1.0	38

#	ARTICLE	IF	CITATIONS
289	Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count. <i>Clinical Colorectal Cancer</i> , 2006, 6, 297-304.	1.0	29
290	Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma. <i>Journal of Clinical Neuroscience</i> , 2006, 13, 595-598.	0.8	13
291	Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas. <i>Pathology</i> , 2006, 38, 145-151.	0.3	3
292	Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. <i>BMC Cancer</i> , 2006, 6, 240.	1.1	79
293	Oxaliplatin and Axonal Na <sup>+</sup> Channel Function In vivo. <i>Clinical Cancer Research</i> , 2006, 12, 4481-4484.	3.2	82
294	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. <i>Human Molecular Genetics</i> , 2006, 15, 443-451.	1.4	138
295	Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. <i>Gynecologic Oncology</i> , 2005, 97, 16-25.	0.6	8
296	Oxaliplatin-induced neurotoxicity and the development of neuropathy. <i>Muscle and Nerve</i> , 2005, 32, 51-60.	1.0	194
297	Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. <i>Familial Cancer</i> , 2005, 4, 105-113.	0.9	47
298	Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1686-1691.	1.1	290
299	Agreement Between Self-Reported Breast Cancer Treatment and Medical Records in a Population-Based Breast Cancer Family Registry. <i>Journal of Clinical Oncology</i> , 2005, 23, 4679-4686.	0.8	99
300	What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?. <i>Lancet Oncology</i> , The, 2005, 6, 581-588.	5.1	59
301	The Y Deletion gr/gr and Susceptibility to Testicular Germ Cell Tumor. <i>American Journal of Human Genetics</i> , 2005, 77, 1034-1043.	2.6	197
302	Biology of Epithelial Ovarian Cancer: Implications for Screening Women at High Genetic Risk. <i>Journal of Clinical Oncology</i> , 2004, 22, 1315-1327.	0.8	140
303	Prognosis of Premenopausal Breast Cancer and Childbirth Prior to Diagnosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 699-705.	0.8	63
304	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 93, 417-421.	0.6	23
305	No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers. <i>Gynecologic Oncology</i> , 2004, 95, 430-436.	0.6	6
306	The fertility- and menopause-related information needs of younger women with a diagnosis of breast cancer: A qualitative study. <i>Psycho-Oncology</i> , 2003, 12, 500-511.	1.0	133

#	ARTICLE	IF	CITATIONS
307	Guidelines for the Treatment of Recurrent and Metastatic Cervical Cancer. <i>Oncologist</i> , 2002, 7, 342-347.	1.9	203
308	Guidelines for the treatment of recurrent and metastatic cervical cancer. <i>Oncologist</i> , 2002, 7, 342-7.	1.9	77
309	Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene defect. <i>Lancet</i> , The, 2001, 357, 1767-1768.	6.3	16
310	The frequency of founder mutations in theBRCA1,BRCA2, andAPC genes in australian Ashkenazi Jews. <i>Cancer</i> , 2001, 92, 440-445.	2.0	45
311	Current management of epithelial ovarian carcinoma: A review. <i>Journal of Surgical Oncology</i> , 2000, 19, 11-19.	1.4	70
312	Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. <i>Nature Genetics</i> , 2000, 24, 197-200.	9.4	260
313	Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 101-111.	1.1	48
314	Intention to Undergo Prophylactic Bilateral Mastectomy in Women at Increased Risk of Developing Hereditary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2250-2257.	0.8	112
315	Attitudes toward Prophylactic Oophorectomy and Screening Utilization in Women at Increased Risk of Developing Hereditary Breast/Ovarian Cancer. <i>Gynecologic Oncology</i> , 1999, 75, 122-129.	0.6	68
316	Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin. <i>Cancer Investigation</i> , 1999, 17, 479-485.	0.6	3
317	Analysis of loss of heterozygosity andKRAS2 mutations in ovarian neoplasms: Clinicopathological correlations. , 1997, 18, 75-83.		42
318	Uterine papillary serous carcinoma. A clinical study. <i>Cancer</i> , 1995, 75, 2239-2243.	2.0	86
319	CURRENT GENITOURINARY CANCER SURGERY. <i>Australian and New Zealand Journal of Medicine</i> , 1991, 21, 492-492.	0.5	0
320	Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. <i>Cytometry</i> , 1985, 6, 327-333.	1.8	427